By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ironwood Pharmaceuticals 

301 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-621-7722 Fax: 617-494-0480


SEARCH JOBS

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma.


Key Statistics


Email:
Ownership: Public

Web Site: Ironwood
Employees:
Symbol: IRWD
 



Industry
Pharmaceutical






Company News
Ironwood (IRWD) Appoints Dr. Christopher Wright As Senior Vice President Of Global Development And Chief Development Officer 4/6/2017 8:17:15 AM
Ironwood (IRWD) Showcases Progress Delivering Innovative Medicines To Patients And Building A Top-Performing Commercial Biotech At R&D Day 2017 3/9/2017 8:18:16 AM
Momenta (MNTA) to Become Neighbors With Biogen (BIIB), Ironwood (IRWD) in Kendall Square Next Year 2/28/2017 6:09:43 AM
Ironwood (IRWD) To Host R&D Day On March 9, 2017 2/24/2017 7:55:37 AM
Ironwood (IRWD) Provides Fourth Quarter And Full Year 2016 Investor Update 2/22/2017 6:56:19 AM
Ironwood (IRWD) To Host Fourth Quarter And Full-Year 2016 Investor Update Call 2/8/2017 6:39:33 AM
Ironwood (IRWD) Appoints Amy Schulman To Board Of Directors 1/5/2017 9:16:03 AM
Ironwood (IRWD) Announces New Drug Application For DUZALLO (Fixed-Dose Combination Of Lesinurad And Allopurinol) Has Been Accepted For FDA Review 1/4/2017 11:11:28 AM
Ironwood (IRWD) and Allergan (AGN) Report Topline Phase IIb Data Supporting Advancement Of Linaclotide Colonic Release-1 (CR1) In IBS-C 12/22/2016 11:18:31 AM
Ironwood (IRWD) And Allergan (AGN) Report Topline Phase IIb Data Supporting Further Investigation Of Linaclotide Colonic Release-2 (CR2) For Abdominal Pain In Non-Constipation Subtypes Of IBS 12/22/2016 11:16:57 AM
12345678910...
//-->